Who founded Immutrin?

Immutrin was founded by Mark Pepys, Gregory Winter, Daniel Christ.

Who are Immutrin's investors?

Immutrin's investors include Cambridge Innovation Capital, Frazier Life Sciences, Qiming Venture Partners, F-Prime Capital, SR One Capital Management.

How much funding has Immutrin raised?

Immutrin has disclosed $173.4M raised across 2 rounds.

Immutrin

5 known investors

Find your way into Immutrin

Your email: who you already know at Immutrin, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Immutrin team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Immutrin is a biotechnology company developing antibody therapies designed to remove systemic amyloid deposits and reverse amyloidosis. Its lead program targets ATTR cardiomyopathy, a progressive form of amyloidosis.

Biotech Medical Devices

Founders & leadership

Mark PepysCo-founder; Emeritus Professor of Medicine at UCL

Gregory WinterCo-founder; Nobel Laureate

Daniel ChristCo-founder; Professor, Faculty of Medicine, UNSW

Investors · 5

Cambridge Innovation Capital✓ confirmed by ImmutrinCambridge · $127K – $12.7M

How we know: the company's own site · Cambridge Innovation Capital's portfolio page · a partner's Signal profile · funding news · open dataset · 5k.vc investor directory · Not right? Tell us

Frazier Life Sciences✓ confirmed by ImmutrinPalo Alto

How we know: Frazier Life Sciences's portfolio page · the company's own site · funding news · open dataset · 5k.vc investor directory · Not right? Tell us

Qiming Venture Partners✓ confirmed by ImmutrinBeijing

How we know: the company's own site · funding news · Not right? Tell us

F-Prime Capitallisted by F-Prime CapitalCambridge · $3M – $10M

How we know: F-Prime Capital's portfolio page · a partner's Signal profile · Not right? Tell us

SR One Capital Managementlisted by SR One Capital ManagementRedwood City

How we know: SR One Capital Management's portfolio page · Not right? Tell us

Funding

SEC filings, press & company announcements

$173.4M disclosed across 2 rounds · 2026

$86.5MSeries AMar 2026 · 2 sources
Source ↗
$87MraisedMar 2026 · 2 sources
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Frequently asked questions

What does Immutrin do?: Immutrin is a biotechnology company developing antibody therapies designed to remove systemic amyloid deposits and reverse amyloidosis. Its lead program targets ATTR cardiomyopathy, a progressive form of amyloidosis.
Who founded Immutrin?: Immutrin was founded by Mark Pepys, Gregory Winter, Daniel Christ.
Who are Immutrin's investors?: Immutrin's investors include Cambridge Innovation Capital, Frazier Life Sciences, Qiming Venture Partners, F-Prime Capital, SR One Capital Management.
How much funding has Immutrin raised?: Immutrin has disclosed $173.4M raised across 2 rounds.